Recent Insider Activity Could Benefit Neurocrine Biosciences, Inc (NBIX)

Roman Campbell

Neurocrine Biosciences, Inc’s filing revealed that its Chief Executive Officer Gano Kyle unloaded Company’s shares for reported $42591.0 on Nov 04 ’25. In the deal valued at $141.97 per share,300 shares were sold. As a result of this transaction, Gano Kyle now holds 140,407 shares worth roughly $20.1 million.

Then, GORMAN KEVIN CHARLES sold 106,322 shares, generating $13,440,281 in total proceeds. Upon selling the shares at $126.41, the Director now owns 514,596 shares.

Before that, KEVIN CHARLES GORMAN bought 106,322 shares. Neurocrine Biosciences, Inc shares valued at $13,654,934 were divested by the Director at a price of $128.43 per share.

Citigroup initiated its Neurocrine Biosciences, Inc [NBIX] rating to a Buy in a research note published on October 21, 2025; the price target was $175. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Goldman began covering NBIX with “Buy” recommendation on July 10, 2025. Needham revised its rating on April 15, 2025. It rated NBIX as “a Buy” which previously was an “a Hold”.

Price Performance Review of NBIX

On Tuesday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock jump 0.87% to $143.19. Over the last five days, the stock has lost -2.84%. Neurocrine Biosciences, Inc shares have risen nearly 19.06% since the year began. Nevertheless, the stocks have risen 4.90% over the past one year. While a 52-week high of $154.61 was reached on 01/30/25, a 52-week low of $84.23 was recorded on 04/09/25.

Levels Of Support And Resistance For NBIX Stock

The 24-hour chart illustrates a support level at 141.38, which if violated will result in even more drops to 139.58. On the upside, there is a resistance level at 144.43. A further resistance level may holdings at 145.68.

How much short interest is there in Neurocrine Biosciences, Inc?

A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-10-15, growing by 0.25 million shares to a total of 4.37 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 4.12 million shares. There was a rise of 5.66%, which implies that there is a positive sentiment for the stock.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.